BPC-157 vs BPC-157 (Oral)
A side-by-side research comparison of BPC-157 and BPC-157 (Oral) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 | BPC-157 (Oral) |
|---|---|---|
| Full name | Body Protection Compound-157 | BPC-157 Oral Formulation (Arginate Salt) |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Upregulates growth factor expression including VEGF and promotes angiogenesis, modulates nitric oxide system, and interacts with the dopaminergic system. | Same mechanism as injectable BPC-157 but delivered orally. Upregulates VEGF, modulates NO system, and promotes gut mucosal healing through direct contact and systemic absorption. |
| Molecular weight | 1419.53 Da | 1419.53 Da |
| Half-life | ~4 hours | ~4 hours (oral bioavailability lower but sustained) |
| Bioavailability | Variable; oral and injectable forms available | ~40-60% oral (arginate salt form) |
| Typical dose | 250-500 mcg per dose | 500 mcg - 1 mg |
| Frequency | 1-2x daily | 1-2x daily |
| Route | Subcutaneous injection (or oral capsules) | Oral capsule (arginate salt) |
BPC-157 reported benefits
- Accelerated tendon and ligament healing
- Gut lining protection and repair
- Neuroprotective effects
- Anti-inflammatory properties
- Muscle tear recovery
BPC-157 (Oral) reported benefits
- Gut healing (direct contact)
- Liver protection
- Oral convenience
- Systemic anti-inflammatory
- No injection required
Related comparisons
Research and educational reference only. Not medical advice.